February 21, 2007 – The Patent Office invalidated Genentech’s Cabilly patent that protects its method for developing antibodies; Theravance reported the FDA accepted its filing for televancin; Noven received a $25 million sales milestone from Shire for an ADHD patch, Daytrana; Genzyme will opt out of a partnership with Dyax for hereditary angioedema; Wyeth lost a civil suit from a woman who alleged that a drug caused her breast cancer; Pharmacylcis received a refuse to file letter from the FDA for a cancer drug; and Hana said its anti-nausea drug Zensana will be delayed. The Centient Biotech 200™ rose 17 points to 4085, an increase of .43%. More details...
